✦ LIBER ✦

Atypical neuroleptics: a new approach in the treatment of negative symptoms

✍ Scribed by Hans-Jürgen Möller

Book ID: 120894960
Publisher: Springer-Verlag
Year: 1999
Tongue: English
Weight: 72 KB
Volume: 249
Category: Article
ISSN: 1433-8491
DOI: 10.1007/PL00014191

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Primary negative symptom schizophrenia—A

Primary negative symptom schizophrenia—A study with the atypical neuroleptic zotepine

✍ W. Fischer; M. Riedel; N. Müller; H.J. Möller 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Covariance of positive and negative symp

Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication

✍ Rajiv Tandon; Saulo C.M. Ribeiro; John R. DeQuardo; Robert S. Goldman; JoAnn Goo 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 230 KB

Coping-orientated treatment and atypical

Coping-orientated treatment and atypical neuroleptics in an integrated treatment approach for patients with schizophrenia

✍ A. Schaub; B. Wolf; A. Gartenmaier; A. Kaiser; N. Müller; H.-J. Möller 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Neuroleptic treatment of negative sympto

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties

✍ Möller, H.-J. 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 1008 KB

P.3.c.010 Severity of negative symptoms

P.3.c.010 Severity of negative symptoms in schizophrenic patients treated with atypical neuroleptic risperidone – follow-up

✍ M. Krzystanek; E. Krzystanek; I. Krupka-Matuszczyk 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Parenteral ziprasidone: a new atypical n

Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?

✍ Matthias Oechsner; Alexei Korchounov 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

This is a report on a case series of five patiens with psychosis in Parkinson's disease who were treated successfully with an intramuscular injection of ziprasidone (10-20 mg) for acute agitation. No deterioration of motor function or other clinically relevant side effects were seen.